Uncomplicated Urinary Tract Infections Market

View All

uncomplicated-uti-treatment-landscape
Uncomplicated UTI Treatment: Challenges and Opportunities in the Market

Urinary tract infection (UTI), also known as acute cystitis, is an infection in any part of the urinary system, including the kidneys, bladder, ureters, and urethra. It is one of the most common infections in local primary care, and UTIs are among the most frequently encountered infections in the outpatient setting...

Find More

Pharma News for Amgen, AstraZeneca, Sanofi, Anavex, Sensorion, GSK
Amgen’s Olpasiran Candidate; GSK’s Novel Antibiotic for Urinary Tract Infections; AstraZeneca and Sanofi’s Beyfortus Approval; FDA Orphan Designation to Anavex’s Anavex2-73; FDA Rare Pediatric Disease Designation to Sensorion’s OTOF-GT; GSK’s Blenrep Fails in Phase III Trial in R/R Multiple Myeloma

Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate  Amgen has reported encouraging mid-stage results for its olpasiran candidate for lowering lipoprotein(a) - a risk factor for atherosclerotic cardiovascular disease - and now plans to move forward with a phase III program as soon as possi...

Find More

uncomplicated-urinary-tract-infections-market
Fight Against the Antibiotic Resistance in the Uncomplicated Urinary Tract Infections Market

Uncomplicated Urinary Tract Infections are one of the most commonly diagnosed infections in the US, with the maximum prevalence in women who are sexually active. A wide range of pathogens can be a reason behind the manifestation of the condition; however, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, ...

Find More